scholarly journals Longer Delay From Chronic Pain to Spinal Cord Stimulation Results in Higher Healthcare Resource Utilization

2016 ◽  
Vol 19 (5) ◽  
pp. 469-476 ◽  
Author(s):  
Shivanand P. Lad ◽  
Frank W. Petraglia ◽  
Alexander R. Kent ◽  
Steven Cook ◽  
Kelly R. Murphy ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Chronic Pain ◽  
Resource Utilization ◽  
Spinal Cord Stimulation ◽  
Healthcare Resource ◽  
Healthcare Resource Utilization

scholarly journals Explantation Rates and Healthcare Resource Utilization in Spinal Cord Stimulation

2017 ◽  
Vol 20 (4) ◽  
pp. 331-339 ◽  
Author(s):  
Jing L. Han ◽  
Kelly R. Murphy ◽  
Syed Mohammed Qasim Hussaini ◽  
Siyun Yang ◽  
Beth Parente ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Resource Utilization ◽  
Spinal Cord Stimulation ◽  
Healthcare Resource ◽  
Healthcare Resource Utilization

Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients

2017 ◽  
Vol 13 (5) ◽  
pp. 291 ◽  
Author(s):  
Mihran Ara Yenikomshian, MBA ◽  
Alan G. White, PhD ◽  
Louis P. Garrison, PhD ◽  
Gary M. Oderda, PharmD, MPH ◽  
Joseph E. Biskupiak, PhD, MBA ◽  
...  
Keyword(s):  
Chronic Pain ◽  
Resource Utilization ◽  
Extended Release ◽  
Healthcare Resource ◽  
Healthcare Resource Utilization ◽  
Abuse Liability ◽  
Commercial Population ◽  
The Difference ◽  
Cost Utilization ◽  
The Cost

Objectives: To estimate healthcare resource utilization, associated costs, and number needed to harm (NNH) from a physician's decision to prescribe extended-release (ER) non-abuse-deterrent opioids (non-ADO) as compared to ER ADOs in a chronic pain population.Design: A 12-month probabilistic simulation model was developed to estimate the reduction of misuse and/or abuse from a physician's prescribing decisions for 10,000 patients. Model inputs included probabilities for opioid misuse and/ or abuse-related events, opioid discontinuation, and switching from ADO to non- ADO. Estimated reductions in abuse associated with ADOs were obtained from positive subjective measures using human abuse liability studies. The model was run separately for commercial, Medicare, Medicaid, and Veterans Administration (VA) populations. The difference in healthcare resource utilization and associated costs (2015 USD) between the ADO and non-ADO simulations was calculated. NNH for non-ADO was also calculated.Results: Misuse and/or abuse-related events for patients prescribed ER non-ADOs ranged from 223−1,410 and associated costs ranged from $20−$98 per patient for commercial and Medicare populations, respectively. Prescribing ER ADOs were associated with 87, 289, 264, and 417 fewer misuse and/or abuse−related events, saving $8, $35, $21, and $29 per patient in commercial, VA, Medicaid, and Medicare populations, respectively. NNH ranged from 185 in the commercial population to 40 in the Medicare population. Results were sensitive to decreases in the probability of misuse and/or abuse events but showed reductions.Conclusions: A physician's decision to prescribe ER ADOs could lead to large reductions in misuse and/or abuse-related events and associated costs across many patient populations.

scholarly journals Using a Physician Survey to Estimate the Economic Burden of Fibromyalgia in China

2020 ◽  
Author(s):  
Wesley Furnback ◽  
Feifei Chen ◽  
Jim Li ◽  
Bruce CM Wang ◽  
Dongfeng Liang
Keyword(s):  
Chronic Pain ◽  
Resource Utilization ◽  
Economic Burden ◽  
Economic Model ◽  
Healthcare Resource ◽  
Healthcare Resource Utilization ◽  
Physician Survey ◽  
Physician Visits ◽  
Blood Tests ◽  
Illness Model

Abstract Background: Fibromyalgia (FM) is a chronic pain disorder with a global prevalence estimated to be between 2 and 3%. In addition to the chronic pain incurred by patients, FM is commonly associated with comorbidities and complications such as depression, anxiety, and sleep disturbances. This study estimates the economic burden of patients with FM in China using a physician survey. Methods: A burden of illness model was constructed using a micro-costing approach to estimate the direct cost associated with FM patients in China. FM-related comorbidities of anxiety, depression, and sleep disturbance were included in the model. Treatment utilization and costs for FM and FM-related comorbidities were included as well as FM-related healthcare resource utilization (physician visits, hospitalizations, blood tests, and radiologic tests). FM treatments included nonsteroidal anti-inflammatory drugs, pregabalin, duloxetine, amitriptyline, tramadol, Chinese medicine, physiotherapy, and acupuncture. The model leveraged the results of a physician survey, which targeted 6 rheumatologists and pain experts each with 5-10 FM patients per month in China. All costs are presented in Renminbi (¥) using spot exchange rates as of May 1, 2020.Results: From the physician survey, the prevalence rate of FM in China was estimated to be 2.8% with 75.8% as female. The economic model estimated the annual per patient direct medical cost of FM to be ¥17,377. Within these costs, FM-medication and treatment costs (¥11,216), healthcare resource utilization (¥4,297), and costs for medications treating FM-related comorbidities (¥1,863) were the highest contributors. Healthcare resource utilization costs were driven by physician visits (¥2,787) followed by radiographic tests (¥808), blood tests (¥508), and hospitalizations (¥194). Conclusion: The prevalence and gender distribution of FM patients in China is similar to those of other countries. The economic model estimates patients with fibromyalgia in China to incur significant economic costs.

Retrospective analysis on the effect of spinal cord stimulation on opioid consumption

2020 ◽  
Author(s):  
Awinita Barpujari ◽  
Michael A Erdek
Keyword(s):  
Spinal Cord ◽  
Chronic Pain ◽  
Retrospective Analysis ◽  
Spinal Cord Stimulation ◽  
Alternative Therapy ◽  
Opioid Consumption ◽  
Opioid Use ◽  
Number Of Patients ◽  
Chronic Pain Conditions ◽  
Post Trial

Aim: Spinal cord stimulation (SCS) is used to clinically manage and/or treat several chronic pain etiologies. A limited amount is known about the influence on patients' use of opioid pain medication. This retrospective analysis evaluated SCS effect on opioid consumption in patients presenting with chronic pain conditions. Materials & methods: Sixty-seven patients underwent a temporary trial device, permanent implant or both. Patients were divided for assessment based on the nature of their procedure(s). Primary outcome was change in morphine equivalent dose (MED), ascertained from preoperative and postoperative medication reports. Results: Postoperative MED was significantly lower in patients who received some form of neuromodulation therapy. Pretrial patients reported an average MED of 41.01 ± 10.23 mg per day while post-trial patients reported an average of 13.30 ± 5.34 mg per day (p < 0.001). Pre-implant patients reported an average MED of 39.14 ± 13.52 mg per day while post-implant patients reported an average MED of 20.23 ± 9.01 mg per day (p < 0.001). There were no significant differences between pre-trial and pre-implant MED, nor between post-trial and post-implant MED. Of the 42 study subjects who reported some amount of pre-intervention opioid use, 78.57% indicated a lower MED (n = 33; p < 0.001), 16.67% indicated no change (n = 7) and 4.76% (n = 2) indicated a higher MED, following intervention. Moreover, SCS therapy resulted in a 26.83% reduction (p < 0.001) in the number of patients with MED >50 mg per day. Conclusion: Spinal cord stimulation may reduce opioid use when implemented appropriately. Neuromodulation may represent alternative therapy for alleviating chronic pain which may avoid a number of deleterious side effects commonly associated with opioid consumption.

Spinal Cord Stimulation for Relief of Chronic Pain in Vasospastic Disorders of the Upper Limbs

1989 ◽  
Vol 5 (2) ◽  
pp. 312
Author(s):  
F. J. ROBAINA ◽  
M. DOMINGUEZ ◽  
M. DIAZ ◽  
J. L. RODRIGUEZ ◽  
J. A. DE VERA
Keyword(s):  
Spinal Cord ◽  
Chronic Pain ◽  
Spinal Cord Stimulation ◽  
Upper Limbs
Sign in / Sign up

Export Citation Format

Share Document